Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due ...

Indivior Pharmaceuticals (INDV) has announced the pricing of its offering of $450M in convertible senior notes due in 2031. The offering size was increased from an initial amount of $400M.

CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private ...

CRISPR Therapeutics AG (NASDAQ:CRSP) shares declined 6.75% on Tuesday after the company revealed plans to raise $350 million through a convertible senior notes offering. The gene-editing firm said it ...

PAR Technology Corporation PAR shares tumbled in Friday's premarket after the company announced plans to raise $250 million through a convertible debt offering to refinance existing notes and fund ...

In recent days, Dave Inc. completed a US$175,000,000 Rule 144A private offering of senior unsecured zero-coupon convertible notes due April 1, 2031, following the release of its fourth-quarter and ...

SAINT HELIER, JE / ACCESS Newswire / January 20, 2026 / Caledonia Mining Corporation Plc (“Caledonia”) today announces the closing of its previously announced upsized offering of 5.875% Convertible ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount ...

CRISPR THERAPEUTICS ® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY ® and the CASGEVY logo are registered trademarks ...